Trident Lifeline Ltd (TLL) is currently trading at 410.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Trident Lifeline Limited is an integrated pharmaceutical and healthcare platform that develops, registers, manufactures and exports formulations, nutraceuticals, cosmetics and medical devices across regulated and emerging markets, operating through a mix of in-house WHO‑GMP facilities, contract manufacturing and majority-owned subsidiaries to deliver global market access. The company reported strong scale-up in FY26 with consolidated revenue of ₹129.0 crore and EBITDA margin expansion to 21.8%, driven by operationalizing new facilities, higher registrations and improving utilization across subsidiaries, marking a meaningful shift from investment phase to revenue generation for Trident Lifeline Limited. Trident owns over 350 products with IPR and claims a registrations pipeline exceeding 2,500 under approval and 300–400 new registrations added annually, indicating a high‑barrier asset base that should produce recurring, multi‑market revenues as the company commercializes approved products across 46 countries. Management targets aggressive growth — aiming to triple consolidated business in three years — underpinned by capacity additions (injectables, liquids, cephalosporin facility planning), recent acquisitions and a demand‑led integration model that prioritizes validated customer demand before large capital deployment for Trident Lifeline Limited.

Over the past 52 weeks, Trident Lifeline Ltd has traded between a low of ₹229.95 and a high of ₹425.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Trident Lifeline Ltd has a market capitalization of approximately 487.63. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Trident Lifeline Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 22.57 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 487.63 Cr, Trident Lifeline Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Trident Lifeline Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Trident Lifeline Ltd is 22.57. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The board approved a preferential issue of 12,22,200 equity shares and up to 5,00,400 fully convertible warrants, each priced at Rs 336.60.

Trident Lifeline reported consolidated net sales of ₹33.72 crore for June 2026, up 42.84% year-on-year.

The company appointed Ms. Smita Kiran Davda and Mr. Sachin Bhandari as Additional Directors in the capacity of Non-Executive Independent Directors with effect from June 13, 2026, subject to shareholder approval.